- Home
- AZN
AZN
AstraZeneca PLC
as 11-20-2024 4:00pm EST
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
| Founded: | 1992 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 234.5B | IPO Year: | 1993 |
| Target Price: | $88.80 | AVG Volume (30 days): | 8.0M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 4.15 | EPS Growth: | 9.79 |
| 52 Week Low/High: | $60.47 - $87.68 | Next Earning Date: | 11-12-2024 |
| Revenue: | $51,206,000,000 | Revenue Growth: | 13.81% |
| Revenue Growth (this year): | 17.69% | Revenue Growth (next year): | 7.95% |
Latest AstraZeneca PLC News
AZN Breaking Stock News: Dive into AZN Ticker-Specific Updates for Smart Investing
Business Wire
21 hours ago
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
Pharmaceutical Technology
a day ago
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
Bloomberg
a day ago
AstraZeneca Is No Longer a Sell for Any Analyst as UBS Upgrades
Zacks
2 days ago
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
TipRanks
2 days ago
AstraZeneca’s Tagrisso recommended for approval in EU by CHMP for certain NSCLC
Pharmaceutical Technology
2 days ago
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
PR Newswire
3 days ago
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
Pharmaceutical Technology
3 days ago
AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership
Compare AZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AZN AstraZeneca PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.